[go: up one dir, main page]

SE0301906D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0301906D0
SE0301906D0 SE0301906A SE0301906A SE0301906D0 SE 0301906 D0 SE0301906 D0 SE 0301906D0 SE 0301906 A SE0301906 A SE 0301906A SE 0301906 A SE0301906 A SE 0301906A SE 0301906 D0 SE0301906 D0 SE 0301906D0
Authority
SE
Sweden
Prior art keywords
hydrogen
new compounds
nhar
nitro
halogen
Prior art date
Application number
SE0301906A
Other languages
Swedish (sv)
Inventor
Rhonan Ford
Frederic Leroux
Michael Stocks
Britt-Marie Swahn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0301906A priority Critical patent/SE0301906D0/en
Publication of SE0301906D0 publication Critical patent/SE0301906D0/en
Priority to PCT/SE2004/001015 priority patent/WO2004113303A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to new compounds of formula (I) in which:X is CR<4> or N; R<1> is -OR<5>, -NHCOR<6> or -NR<6>R<7>; R<2 >is hydrogen, Oar<1> or -NHAr<1> wherein Ar<1> is aryl optionally substituted with one or more of R<8>, -OR<8>, -NR<8>R<9>, -CONR<8>R<9>, -COOR<8>, -NR<8>COR<9>, -SR<8>, -SO2NR<8>R<9>, -NR<8>SO2 R<9>, halogen, cyano, or nitro; R<3> is hydrogen or -NHAr<2> wherein Ar<2> is benzene optionally substituted with one or more of R<8>, -OR<8>, -NR<8>R<9>, halogen or nitro, wherein R<2> and R<3> is not simultaneously hydrogen; a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
SE0301906A 2003-06-26 2003-06-26 New compounds SE0301906D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0301906A SE0301906D0 (en) 2003-06-26 2003-06-26 New compounds
PCT/SE2004/001015 WO2004113303A1 (en) 2003-06-26 2004-06-23 INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301906A SE0301906D0 (en) 2003-06-26 2003-06-26 New compounds

Publications (1)

Publication Number Publication Date
SE0301906D0 true SE0301906D0 (en) 2003-06-26

Family

ID=27656639

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301906A SE0301906D0 (en) 2003-06-26 2003-06-26 New compounds

Country Status (2)

Country Link
SE (1) SE0301906D0 (en)
WO (1) WO2004113303A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2357957C2 (en) * 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. P38 inhibitors and application methods
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
DE102004028862A1 (en) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-aminoindazoles
AU2006283592A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
KR101011957B1 (en) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 PI3 MAP P Kinase Inhibitor and Method of Use thereof
JP5131990B2 (en) 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド Kinase inhibitors and methods of use thereof
CA2672719A1 (en) 2006-12-19 2008-06-26 F. Hoffmann-La Roche Ag Pyrazolo [3, 4 -d] pyrimidine p38 map kinase inhibitors
AR071780A1 (en) * 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl BICYCLE CARBONILAMINO-PIRAZOLES CARBAMILILE DERIVATIVES AS PROFARMACOS
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP2013522292A (en) * 2010-03-16 2013-06-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Indazole compounds and their use
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CA2889572C (en) * 2012-11-08 2019-03-05 Pfizer Inc. Heteroaromatic compounds as dopamine d1 ligands
SI3417851T1 (en) 2013-09-09 2020-11-30 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
JP6491202B2 (en) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Polycyclic inhibitors of cyclin dependent kinase 7 (CDK 7)
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
EP3268362B1 (en) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP7028766B2 (en) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitor of cyclin-dependent kinase
EA201891626A1 (en) * 2016-01-21 2019-04-30 Зибо Биополар Чангшенг Фармасьютикал Ко. Лтд. BLUTON TYROSINKINASE INHIBITORS
US10793566B2 (en) 2016-01-21 2020-10-06 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
CA3017567A1 (en) 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase
WO2020005807A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
WO2021075476A1 (en) 2019-10-18 2021-04-22 武田薬品工業株式会社 Heterocyclic compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL340412A1 (en) * 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020506A1 (en) * 2000-08-22 2002-07-09 Glaxo Group Ltd PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS
CN1300116C (en) * 2001-04-16 2007-02-14 卫材株式会社 1H-Indazole compound
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
WO2004113303A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
SE0301906D0 (en) New compounds
ES2145922T3 (en) USEFUL SPYRO-AZABICYCLIC COMPOUNDS IN THERAPY.
SE0102439D0 (en) New compounds
UY26139A1 (en) COMPOSITIONS OF MEDICINAL PRODUCTS BASED ON ANTICHOLINERGICALLY ACTIVE AND BETA-MIMETIC COMPOUNDS
AR034259A1 (en) POLYMORPHES OF AN EPOTILONE ANALOG, PROCESSES TO PREPARE THEM AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY28510A1 (en) CHEMICAL COMPOUNDS
DE68919010D1 (en) Purine compounds, processes for their preparation and pharmaceutical preparations.
ECSP088404A (en) NEW IMIDAZO DERIVATIVES [4,5-B] PIRIDINE AS INHIBITORS OF THE GLUCÓGENO SINTASA QUINASA 3, FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS
TR200302214T4 (en) Pteridine compounds used for the treatment of psoriasis
NO802352L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE IMIDAZOLD DERIVATIVES.
EA200400664A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING METHFORMIN AND GLIBENCLAMIDE, APPLIED TO THE TREATMENT OF TYPE II DIABETES
ATE25246T1 (en) TRIPHENYLIMIDAZOLYLOXYALKANOIC ACIDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
SE0100569D0 (en) New compounds
PA8432901A1 (en) PIRIDILPIRROL COMPOUNDS
BR9813651A (en) Antipicornoviral compounds and methods for their use and preparation
TR200200263T2 (en) New selective retinoid agonists
BRPI0415203A (en) restructured pentanols, a process for their production and use as anti-inflammatory agents
AR001769A1 (en) Benzamide enterokinetics pharmaceutical compositions containing them, a process for the preparation of said pharmaceutical compositions, the use of said compounds for the manufacture of medicines and a process for their preparation.
BR0315958A (en) Compound, pharmaceutical composition, process for preparing a compound, new intermediates and use of the compound
IT1255704B (en) HETEROCYCLIC AMINES USEFUL IN THERAPY OF ASTHMA AND AIRWAY INFLAMMATION
ES2115220T3 (en) NEW USE OF BIS-HETERO-CYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF.
ATE288919T1 (en) THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
PE20050393A1 (en) BENZOPYRANE COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF INFLAMMATION-RELATED CONDITIONS
ATE260252T1 (en) THIOCOLCHICIN DERIVATIVES WITH ANTI-INFLAMMATORY AND MUSCLE RELAXANT EFFECT
PT861250E (en) AMIDINE AND ISOTIOUREIA DERIVATIVES AS NITRIC OXIDE INHIBITORS